-+ 0.00%
-+ 0.00%
-+ 0.00%

Aquestive Therapeutics Announced Topline Results From Its Pediatric Study For Anaphylm (Epinephrine) Sublingual Film In Patients Aged 7 To 17 And Weighing Over 30kgs With A Personal History Of Allergic Reactions, FDA Application Acceptance Expected In Q2 2025

Benzinga·04/01/2025 11:05:35
Listen to the news
  • Reports positive pharmacokinetic (PK) results from the recently completed pediatric study for Anaphylm.
  • Completes submission of its New Drug Application (NDA) for Anaphylm to the FDA; NDA acceptance expected in Q2 2025.